CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Dec. 31, 2022
Cash flows from operating activities:
Net income (loss)			$ (3,931,830)	$ (1,986,016)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization	$ 826,795	$ 1,560,870	1,653,590	3,121,740
Bad debt expense (recoveries)			4,499	(106,940)
Inventory and sample inventory reserve			41,195	(14,858)
Lease expense			64,081	56,778
Derivative liability				(460,000)
Deferred revenue			(281,372)	121,146
Gain on settlement with Vivus				(3,389,941)
Employee stock-based compensation			173,652	658,093
Changes in operating assets and liabilities:
Accounts receivable			(470,984)	(3,185,558)
Inventories			33,266	(1,374,350)
Prepaid expenses and other current assets			326,992	1,058,333
Accounts payable			(22,668)	(2,653,421)
Accrued expenses			1,143,909	(1,429,156)
Other current liabilities			24,586	177,550
Other long-term liabilities			(79,349)	(68,909)
Net cash used in operating activities			(1,320,433)	(9,475,509)
Cash flows from financing activities:
Payment of promissory note			(721,034)	(1,076,974)
Net cash used in financing activities			(721,034)	(1,076,974)
Net decrease in cash			(2,041,467)	(10,552,483)
Cash, beginning of period			9,426,264	23,847,572	$ 23,847,572
Cash, end of period	$ 7,384,797	$ 13,295,089	7,384,797	13,295,089	$ 9,426,264
Supplemental cash flow information:
Cash paid for interest during the period			278,966	153,026
Noncash Items:
Noncash decrease in accrued expenses related to Vivus settlement				(6,520,283)
Noncash decrease in accrued inventory purchases related to Vivus Settlement				(14,203,905)
Noncash increase in promissory note related to Vivus settlement				10,024,785
Noncash increase in inventory due to API reclass			(439,353)
Noncash decrease in API purchase commitment			459,422	$ 6,232,489
Noncash decrease in other current assets: API purchase commitment			(20,069)
Noncash issuance of common stock to non-employee			$ 3